Candel Therapeutics, Inc. — Director's Dealing 2021

Jul 27, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Candel Therapeutics, Inc. (CADL)
CIK: 0001841387
Period of Report: 2021-07-26

Reporting Person: Aguilar-Cordova Estuardo (Director, Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	853786	Direct
Common Stock	2074942	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.46	2028-08-17	Common Stock (12205)		Direct
Stock Option (Right to Buy)	$1.46	2028-11-12	Common Stock (76717)		Direct
Series B Preferred Stock	$		Common Stock (162137)		Direct

Footnotes

F1: Shares held by the Estuardo Aguilar-Cordova 2020 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.

F2: 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in three substantially equal annual installments thereafter.

F3: This option shall vest and become exercisable in four substantially equal annual installments, with the first installment vesting on October 13, 2018.

F4: The Series B Preferred Stock has no expiration date.

F5: Includes 32,399 shares held jointly with spouse.